On May 10, 2022, it was announced that the Eisai lenvatinib dose exchange program has been expanded to cover all indicated dose reductions for patients with endometrial cancer who require a new prescription. The program will allow dose exchanges for up to 15 days of a patient's current dose for one that is lower, once per quarter, and at no cost.
For more information, read the news article.
The American Society of Clinical Oncology (ASCO) has updated its 2022 guideline for biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer to include the Oncotype DX Breast Recurrence Score® test. This test is recommended for use in postmenopausal patients with up to three positive axillary lymph nodes, irrespective of clinical risk.
For more information, read Exact Sciences' announcement and the ASCO guideline update.
On Monday, April 18, 2022, the U.S. Food and Drug Administration (FDA) approved Alymsys® (bevacizumab-maly), a biosimilar to Avastin® (bevacizumab). Alymsys' approved indications include:
Metastatic colorectal cancer in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment
Metastatic colorectal cancer in combination with fluoropyrimidine-irinotecan- or fluoropyrimidineoxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
Read Brand Institute's announcement for more information.
Effective April 16, 2022, Secretary of Health and Human Services (HHS) Xavier Becerra renewed the COVID-19 public health emergency that has existed nationwide since January 27, 2020.
For more information, visit the HSS website.
On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved lutetium Lu 177 vipivotide tetraxetan for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
Read the FDA announcement.
Read Novartis' announcement.